Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 29 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

28%

8 trials in Phase 3/4

Results Transparency

31%

4 of 13 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (6)
Early P 1 (1)
P 1 (4)
P 2 (7)
P 3 (5)
P 4 (3)

Trial Status

Completed13
Unknown7
Not Yet Recruiting4
Recruiting3
Withdrawn1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT07386678Not Yet Recruiting

Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment

NCT06425419Phase 1Not Yet Recruiting

The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy

NCT06033703Phase 1Recruiting

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

NCT07162818Phase 4CompletedPrimary

Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

NCT04136366Phase 3CompletedPrimary

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT06818721Phase 2Not Yet Recruiting

Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment

NCT06583798Completed

Outcomes of Retinal Re-surgeries in Silicone Oil Filled Eyes

NCT06541574Phase 2RecruitingPrimary

Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

NCT05660447Phase 2Active Not Recruiting

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT06289205Phase 1RecruitingPrimary

"Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"

NCT04891991Phase 2Completed

Intravitreal Infliximab for Proliferative Vitreoretinopathy

NCT06166914Not ApplicableCompleted

Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment

NCT03727776Early Phase 1CompletedPrimary

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

NCT04830878Phase 1WithdrawnPrimary

Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients

NCT05561569Not ApplicableUnknown

Air Versus Gas Tamponade in Primary Retinal Detachment

NCT05538156Not ApplicableNot Yet Recruiting

Internal Limiting Membrane Peeling in Retinal Detachment Surgery

NCT04580147Phase 2Unknown

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

NCT02192970Phase 2Completed

Bevacizumab Against Recurrent Retinal Detachment

NCT04682054Not ApplicableUnknown

Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics

NCT04490876CompletedPrimary

Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy

Scroll to load more

Research Network

Activity Timeline